Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 6Phase 1/2 5Phase 3 2Phase 4 1

Status

Terminated 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 11INDUSTRY 5NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 439Neoplasms 364Breast Neoplasms 261Colorectal Neoplasms 245Neoplasm Metastasis 217Melanoma 210Leukemia, Myeloid, Acute 188Multiple Myeloma 187Pancreatic Neoplasms 183Ovarian Neoplasms 181Recurrence 175Prostatic Neoplasms 161Lymphoma, Non-Hodgkin 142Stomach Neoplasms 133Squamous Cell Carcinoma of Head and Neck 128Lung Neoplasms 126Lymphoma 121Carcinoma, Hepatocellular 117Carcinoma, Renal Cell 102Triple Negative Breast Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 99Glioblastoma 98Advanced Solid Tumor 94Leukemia 93Small Cell Lung Carcinoma 91Lymphoma, Large B-Cell, Diffuse 90Head and Neck Neoplasms 87Advanced Solid Tumors 85Endometrial Neoplasms 81Myelodysplastic Syndromes 78

Interventions

blinatumomab 2siremadlin 1sabatolimab 1posaconazole 1midostaurin 1Midazolam 1Idarubicin 1Daunorubicin 1Cytarabine 1Azacitidine 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Neoplasm, Residual × Clear all
NCT04521231 2026-05-28

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Amgen

Phase 1/2 Active not recruiting
181 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07134088 2026-05-15

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Amgen

Phase 1/2 Active not recruiting
104 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

NCT04623216 2025-10-16

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

Novartis

Phase 1/2 Terminated
24 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03441464 2022-02-25

Feasibility of the LUM Imaging System for Detection of Prostate Cancer

Lumicell, Inc.

Phase 1/2 Terminated
9 enrolled
Genitourinary

Prostatic Neoplasms, Neoplasm, Residual

NCT03760445 2020-01-09

HDM201 Added to CT in R/R or Newly Diagnosed AML

Novartis

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡